Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AstraZeneca PLC (NYSE:AZN)

29.70
Delayed Data
As of May 31
 -0.18 / -0.60%
Today’s Change
27.68
Today|||52-Week Range
34.88
-12.52%
Year-to-Date
Spurious Relypsa Bear Report Built on Unreliable Safety Data
May 31 / TheStreet.com - Paid Partner Content
Bret Jensen Reporting for Duty
May 27 / TheStreet.com - Paid Partner Content
AstraZeneca Reports Positive Phase III Data on Faslodex
May 31 / Zacks.com - Paid Partner Content
Relypsa Scores Big Win When Pharma Rival Flops at FDA
May 27 / TheStreet.com - Paid Partner Content
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
May 30 / Zacks.com - Paid Partner Content
Lilly's (LLY) R&D Update, Targets 20 New Launches by 2023
May 25 / Zacks.com - Paid Partner Content
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
May 30 / Zacks.com - Paid Partner Content
Why Relypsa Inc. Is Moving Higher Today
May 23 / MotleyFool.com - Paid Partner Content
Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pip...
May 28 / MotleyFool.com - Paid Partner Content
Here's What Pfizer's Telling Us About Biotech M&A
May 21 / MotleyFool.com - Paid Partner Content
Shares Of Relypsa Inc. Are Surging Again -- Here's Why
May 27 / MotleyFool.com - Paid Partner Content
AstraZeneca's Severe Asthma Drug Positive in Phase III
May 18 / Zacks.com - Paid Partner Content
Interested in Medivation? Take a Number!
May 27 / MotleyFool.com - Paid Partner Content